Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

Edward B. Garon, MD, associate professor of medicine, David Geffen School of Medicine, University of California, Los Angeles, discusses the expanding treatment landscape in lung cancer.

In recent years, several immune checkpoint inhibitors have been approved in the lung cancer space, including ​the combination of ipilimumab (Yervoy) ​and nivolumab (Opdivo), says Garon.

Moreover, several targeted therapies, such as RET and MET exon 14 skipping ​TKIs, ​have further expanded the armamentarium, Garon concludes.